Posted in Constellation in the News, Newsroom
Targeting Chromatin Adaptors to Suppress MYC, a Gene Dysregulated in Wide Range of Malignancies, Represents Promising Therapeutic Approach in Oncology CAMBRIDGE, Mass. – September 26, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced the publication of a paper in the Proceedings of the National Academy of [...]
Read more »
Posted in Constellation in the News, Newsroom
CAMBRIDGE, Mass. – June 6, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life [...]
Read more »
Posted in Constellation in the News
- Dr. Michael Cooper Appointed Chief Medical Officer - Dr. Steven Paul Elected to Board of Directors CAMBRIDGE, Mass. – February 1, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the expansion of its leadership team with the [...]
Read more »
Posted in Constellation in the News, Newsroom
MMRF Biotech Investment Awards Provide Funding to Industry to Advance Myeloma Therapies NORWALK, Conn. – January 6, 2011 – The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, [...]
Read more »
Posted in Constellation in the News, Newsroom
-Accomplished Executive Brings Broad Drug Discovery and Development Experience- CAMBRIDGE, MA – January 4, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the appointment of Dr. James E. Audia as Chief Scientific Officer. Audia joins Constellation following a [...]
Read more »
